|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2500110581 |
|
最近更新日期: Date of Last Refreshed on: |
2025-10-16 09:04:10 |
|
注册时间: Date of Registration: |
2025-10-16 00:00:00 |
|
注册号状态: |
补注册 |
|
Registration Status: |
Retrospective registration |
|
注册题目: |
全自主超声扫查机器人的疾病诊断 |
|
Public title: |
Diagnostic Application of a Fully Autonomous Ultrasound Scanning Robot |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
全自主超声扫查机器人的疾病诊断 |
|
Scientific title: |
Diagnostic Application of a Fully Autonomous Ultrasound Scanning Robot |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
吕发勤 |
研究负责人: |
吕发勤 |
|
Applicant: |
Faqin Lv |
Study leader: |
Faqin Lv |
|
申请注册联系人电话: Applicant telephone: |
+86 10 5797 6770 |
研究负责人电话:
Study leader's |
+86 10 5797 6770 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
lvjin8912@163.com |
研究负责人电子邮件: Study leader's E-mail: |
lvjin8912@163.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
北京市海淀区永定路69号 |
研究负责人通讯地址: |
北京市海淀区永定路69号 |
|
Applicant address: |
No. 69, Yongding Road, Haidian District, Beijing |
Study leader's address: |
No. 69, Yongding Road, Haidian District, Beijing |
|
申请注册联系人邮政编码: Applicant postcode: |
100039 |
研究负责人邮政编码: Study leader's postcode: |
100039 |
|
申请人所在单位: |
中国人民解放军总医院第三医学中心超声医学科 |
||
|
Applicant's institution: |
Department of Ultrasound, The Third Medical Center of Chinese PLA General Hospital |
||
|
研究负责人所在单位: |
中国人民解放军总医院第三医学中心超声医学科 |
||
|
Affiliation of the Leader: |
Department of Ultrasound, The Third Medical Center of Chinese PLA General Hospital |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
伦审科研第(KY2024-025)号 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
中国人民解放军总医院医学伦理委员会 |
||
|
Name of the ethic committee: |
Medical Ethics Committee of Chinese PLA General Hospital |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2024-06-13 00:00:00 | ||
|
伦理委员会联系人: |
医学伦理委员会办公室 |
||
|
Contact Name of the ethic committee: |
Office of Medical Ethics Committee |
||
|
伦理委员会联系地址: |
北京市海淀区永定路69号 |
||
|
Contact Address of the ethic committee: |
No. 69, Yongding Road, Haidian District, Beijing |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 10 5797 6902 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
中国人民解放军总医院第三医学中心 |
||||||||||||||||||||||
|
Primary sponsor: |
The Third Medical Center of Chinese PLA General Hospital |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
中国北京市海淀区永定路69号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
No. 69, Yongding Road, Haidian District, Beijing |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
国家重点研发计划 (2022YFB473500) |
||||||||||||||||||||||
|
Source(s) of funding: |
National Key Research and Development Program of China (2022YFB473500) |
||||||||||||||||||||||
|
研究疾病: |
需要超声检查的常见临床疾病(健康体检人群及常规诊疗对象) |
||||||||||||||||||||||
|
Target disease: |
Common clinical conditions requiring ultrasound examination (health check-up population and routine diagnostic cases) |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
随机交叉对照 |
||||||||||||||||||||||
|
Study design: |
Cross-over |
||||||||||||||||||||||
|
研究目的: |
本研究为随机交叉非劣效性设计:每位受试者同次访视内依次接受 RAUS 与 HCUS 两种检查,随机分配为 A(RAUS→HCUS)或 B(HCUS→RAUS)序列;两次检查间隔≥10 分钟以降低学习与残留效应。影像去标识并一致化预处理,由盲法双读+裁决。统计分析在配对框架下进行,并用 GLMM/LMM 控制序列/周期/中心效应,如发现残留效应则开展 Grizzle 或第一周期敏感性分析。 |
||||||||||||||||||||||
|
Objectives of Study: |
Randomized crossover non-inferiority design: each participant receives both RAUS and HCUS in a single visit, randomized to sequence A (RAUS→HCUS) or B (HCUS→RAUS), with an interval ≥10 minutes to mitigate learning and carry-over. Images are de-identified and standardized for blinded double-reading plus adjudication. Analyses are paired with supportive GLMM/LMM adjusting for sequence/period/center; Grizzle or first-period sensitivity analyses if carry-over is detected. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
1.年龄18–75岁,男女不限; 2.接受常规健康体检或临床超声检查者; 3.自愿签署书面知情同意。 |
||||||||||||||||||||||
|
Inclusion criteria |
1. Age: 18-75 years old, gender not limited; 2. Those who have undergone regular health check-ups or clinical ultrasound examinations; 3. Voluntarily sign written informed consent. |
||||||||||||||||||||||
|
排除标准: |
1.孕妇或哺乳期妇女; 2.无法耐受检查体位者; 3.装有金属植入物或心脏起搏器影响成像者; 4.有严重心肺疾病或精神障碍者; 5.研究者认为不宜参加者。 |
||||||||||||||||||||||
|
Exclusion criteria: |
1. Pregnant or lactating women; 2. Those who cannot tolerate the examination position; 3. Those with metal implants or cardiac pacemakers that affect imaging; 4. Those with severe heart and lung diseases or mental disorders; 5. The researchers believe that it is not advisable to participate. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2024-05-09 00:00:00至 To 2025-10-31 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2024-06-23 00:00:00 至 To 2025-05-10 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
结束 /Completed |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
随机序列由独立统计学专家使用计算机随机数生成器(SPSS 26.0 随机数模块)产生,采用区组随机法(区组大小为4)。随机序列由非研究成员保管,分配隐藏通过不透明、依次编号封袋完成。 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
The random number sequence was generated by an independent statistician using a computer-based random number generator (SPSS version 26.0). Block randomization (block size = 4) was applied. The randomization list was kept by a non-investigator, and allocation concealment was maintained using sealed, opaque, sequentially numbered envelopes. |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
受试者与操作者因干预性质无法盲法;影像判读专家对采集模式保持盲态。所有图像/视频在判读前进行一致化预处理(去标识、灰度标准化、统一帧率与分辨率),并进行判读者一致性训练与校准;判读后记录对采集模式的猜测以评估盲法有效性。 |
|
Blinding: |
Participants and operators were not blinded due to the nature of the intervention; image reviewers were blinded to acquisition mode. Prior to review, all images/clips underwent standardized preprocessing (de-identification, gray-scale normalization, unified frame rate and resolution), and readers received calibration training. After ratings, readers guessed the acquisition mode to assess blinding effectiveness. |
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
是Yes |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
研究结束后,通过ResMan(www.medresman.org.cn)方式共享 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
After the end of the study, it was shared by ResMan (www.medresman.org.cn). |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
CRF;EDC |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
CRF;EDC |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
暂未确定/Not yet |